Australia to allow prescription of MDMA and psilocybin for treatment-resistant mental illnesses
The Guardian, February 3, 2023
After decades of “demonisation”, psychiatrists will be able to prescribe MDMA and psilocybin in Australia from July this year.
The Therapeutic Goods Administration made the surprise announcement on Friday afternoon.
Australia is legalising mushrooms and MDMA for medical use
Dazed, February 3, 2023
Australia is to become the first country to recognise MDMA and magic mushrooms as medicine. The news was announced this afternoon (February 3), with both drugs set to be prescribed in cases of treatment-resistant mental illnesses.
TGA approves MDMA and psilocybin for therapeutic use in ‘controlled medical settings’
The Australian, February 3, 2023
Australia will allow psychedelic drugs to be used in the treatment of specific health conditions from July 1.
On Friday the Therapeutic Goods Administration (TGA) announced changes to the classification of psilocybin, a naturally occurring psychedelic compound, and MDMA, allowing the prescription of medicines containing these compounds.
Australia approves medical magic mushrooms and ecstasy
Deutsche Welle, February 3, 2023
Australian authorities have announced that they will allow MDMA and psilocybin — the respective active ingredients of ecstasy pills and magic mushrooms — for medical treatments.
Australia to legalise use of MDMA and magic mushrooms for treating depression
WION, February 3, 2023
The drug watchdog of Australia on Friday announced that the authorities will be soon legalising psychedelic substances MDMA and psilocybin, which are commonly known as magic mushrooms and ecstasy, for treating patients who are suffering from depression and post-traumatic stress.
Australia becomes first country to recognise psychedelics as medicines
Sydney Morning Herald, February 3, 2023
Australia has become the first country to recognise psychedelics as medicines, after the Therapeutic Goods Administration took researchers by surprise and approved the psychedelic substances in magic mushrooms and MDMA for use by people with certain mental health conditions.
Australia to Legalize MDMA And Magic Mushrooms for Medical Use
Voice of America, February 3, 2023
Australia announced on Friday that psychedelic substances MDMA and psilocybin — more commonly known as ecstasy and magic mushrooms — will soon be used in the treatment of depression and post-traumatic stress. The Therapeutic Goods Administration (TGA) has found that the altered state of consciousness provided by these drugs can help patients.
TGA approves MDMA, psilocybin for mental health treatment
Business News Australia, February 3, 2023
Australia’s therapeutics regulator has announced today that psychiatrists will soon be able to prescribe psychedelic drugs MDMA and psilocybin to treat patients suffering from post-traumatic stress disorder (PTSD) and depression.
MDMA and Psilocybin Are Approved as Medicines for the First Time
Wired, February 3, 2023
In a world-first, Australia has announced it will officially recognize MDMA and psilocybin as medicines.
MDMA and psilocybin approved by TGA for medical use in Australia
7 News, February 3, 2023
People suffering serious mental health conditions will be able to be prescribed psychedelic drugs MDMA and psilocybin within six months.
The Therapeutic Good Administration made the decision following calls to reclassify the substances, but only specifically authorised psychiatrists will be able to prescribe them.
MDMA and psilocybin approved to treat some mental health conditions from July 1
9 News, February 3, 2023
MDMA and psilocybin have been approved to treat some mental health conditions by Australia’s health regulatory body.
The Therapeutic Goods Administration (TGA) has approved the prescription of MDMA for treating post-traumatic stress disorder and psilocybin (the active ingredient in magic mushrooms) for treatment-resistant depression from July 1.
MDMA and magic mushrooms approved for medical use in Australia after TGA ruling
Sky News, February 3, 2023
MDMA and psilocybin have been approved for use by psychiatrists to treat people suffering from serious mental health conditions.
The Therapeutic Goods Administration (TGA) on Friday approved the prescription of MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression.
TGA approves psilocybin and MDMA for use in treating depression and PTSD
ABC News, February 3, 2023
Australia’s medical regulator has approved the use of psychedelics to treat some mental health conditions, making the country one of the first in the world to “officially recognise MDMA and psilocybin as medicines”.
The banker and the soprano who became psychedelic pioneers
The Australian: Business Review, December 16, 2022
Feature Article from The Australian: Business Review.
Famed investment banker Peter Hunt and trail-blazing soprano Tania de Jong’s controversial mission to legalise psychedelics has both brought them closer and been their biggest challenge.
Interview with Professor David Nutt
ABC 774 Melbourne with Ali Moore, December 1, 2022
Professor David Nutt is interviewed on ABC 774 Melbourne with Ali Moore.
Professor David Nutt in Australia to Advocate for Psychedelic-Assisted Therapies
The Canberra Times, November 28, 2022
The Canberra Times features Vanessa’s story, along with the presence of Professor David Nutt (Head of Neuropsychopharmacology at Imperial College London) touring Australia to present keynotes on Psychedelic-assisted therapies: History, Neuroscience and Myths, were both advocating in Canberra this week for the Therapeutic Goods Administration to reschedule MDMA and psilocybin.
Experts call for Medicinal Psychedelics to be Approved as Mental Health Treatment
7 News - Sunrise, November 25, 2022
Professor David Nutt was interviewed on Sunrise, explaining how MDMA can help people with PTSD and the evidence behind the therapies as to why it should be approved in Australia.
The push for using psychedelics in trauma treatment | ABC News
ABC News Australia, November 25, 2022
Professor David Nutt and Vanessa were featured on ABC News Australia, explaining how psychedelic-assisted therapies can help a range of people with mental illnesses, the evidence behind the therapies and why it should be approved in Australia. The segment also briefly addresses the Therapeutic Goods Administration’s decision on psychedelic-assisted therapies to be implemented in the Australia Mental Health system.
Interview with Professor David Nutt on the Neil Mitchell Program
3AW Mornings, November 24, 2022
Professor David Nutt, head of Neuropsychopharmacology at Imperial College London, was interviewed on the Neil Mitchell program, and discussed how psychedelic-assisted therapies could help people with treatment-resistant PTSD and depression, the effects and differences between Psilocybin and MDMA, uncovering myths on addiction and government regulation.
Interview with Professor David Nutt on Drive with Richard Glover
ABC Sydney, November 24, 2022
Professor David Nutt, head of Neuropsychopharmacology at Imperial College London, was interviewed on the Drive with Richard Glover explaining the neuroscience and processes behind how psychedelic-assisted therapies (psilocybin, MDMA and cannabis) can be used to treat treatment-resistant patients suffering from mental illnesses. Professor David Nutt also uncovers the myths regarding psychedelics, the political influence on these substances and how the rescheduling of Psilocybin and MDMA can help treat severely treatment-resistant patients with depression and PTSD.